On July 28, 2022, PharmaCyte Biotech, Inc. issued a statement in response to Iroquois Capital Management, LLC's filing of a preliminary consent statement to commence a consent solicitation in lieu of a stockholder meeting. The Company stated that Iroquois Capital is seeking the consent of the Company's shareholders to change various Company Bylaws, expand the size of the Company's Board of Directors (Board) from 7 to 15, and elect Iroquois Capital's entire slate of 8 directors to the Board. The Company added that it has serious concerns with the recent action taken by Iroquois Capital and portends trouble ahead for the Company and its shareholders.
Delayed
Other stock markets
|
5-day change | 1st Jan Change | ||
2.09 USD | 0.00% | -3.98% | -3.24% |
Quarterly revenue - Rate of surprise
1st Jan change | Capi. | |
---|---|---|
-3.24% | 17.67M | |
+32.36% | 694B | |
+29.72% | 593B | |
-1.60% | 371B | |
+20.07% | 331B | |
+6.04% | 290B | |
+14.53% | 239B | |
-3.15% | 209B | |
+10.09% | 209B | |
+9.27% | 169B |
- Stock Market
- Equities
- PMCB Stock
- News PharmaCyte Biotech, Inc.
- PharmaCyte Biotech Issues a Statement in Response to Iroquois Capital’s Preliminary Consent Statement